#AbeoIt is amazing chart with invesetor or speculator
5.00$ it is good point to build Buying centers with stop loss under 3.50 $ for short term
First target for speculator 8.00 to8.70$
First Target for invesetor 21$ then 49$
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.80 USD
−63.73 M USD
0.00 USD
43.12 M
About Abeona Therapeutics Inc.
Sector
Industry
CEO
Vishwas Seshadri
Website
Headquarters
Cleveland
Founded
1974
FIGI
BBG000DT5D52
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
ABEOABEO stock presents one of the best opportunities in the US market, with target prices well above $100. It is an excellent stock for investors. Currently, the stock is in a weekly upward trend and has broken through a strong supply zone from which it had bounced multiple times before. Now, it is pul
ABEO Long PositionABEO has a nice Long setup .
Ma cross 32/72 strategy on weekly timeframe
with 1.5 reward to risk ratio .
Entry around 4.78 cents
Stop is at 3.63 cents , which is the low of the bottom of the candle of the MA cross
target is 6.50 cents
, indicators on chart is insane oscillator from T
50/50 triangle, but still below the 200 (bearish)looks like a picture-perfect triangle. Wait for confirmation and good luck.
ABEO LongAbeona Therapeutics Inc is a leading clinical-stage biopharmaceutical company. The Company develops novel gene therapies for life-threatening rare diseases. I guess the stock can surge at least to $4.94.
My trade levels:
Entry: $3.92
Take profit: $4.94
Stop loss: $3.59
Risk/reward: 3.09
Abeona Therapeutics Inc.** risky investment opportunity, $200m market capital **
Happy with the risk?
On the above 10-day chart price action has corrected a massive 95% from a high of $20 in early 2018. A number of reasons now exist to be bullish. Why?
1) Bullish divergences. Since the ‘great buy’ signal price action h
ABEO | Bullish All Year | LongAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa
Watch this one!Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa
$ABEO Next Target PTs .60-1 and higher Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of ABEO is 4.84 USD — it has decreased by −0.21% in the past 24 hours. Watch Abeona Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Abeona Therapeutics Inc. stocks are traded under the ticker ABEO.
ABEO stock has risen by 12.04% compared to the previous week, the month change is a −7.46% fall, over the last year Abeona Therapeutics Inc. has showed a −37.63% decrease.
We've gathered analysts' opinions on Abeona Therapeutics Inc. future price: according to them, ABEO price has a max estimate of 25.00 USD and a min estimate of 14.00 USD. Watch ABEO chart and read a more detailed Abeona Therapeutics Inc. stock forecast: see what analysts think of Abeona Therapeutics Inc. and suggest that you do with its stocks.
ABEO reached its all-time high on May 22, 1981 with the price of 5,437,500.00 USD, and its all-time low was 2.19 USD and was reached on Feb 24, 2023. View more price dynamics on ABEO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ABEO stock is 2.91% volatile and has beta coefficient of 0.63. Track Abeona Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Abeona Therapeutics Inc. there?
Today Abeona Therapeutics Inc. has the market capitalization of 236.19 M, it has increased by 12.59% over the last week.
Yes, you can track Abeona Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Abeona Therapeutics Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
ABEO earnings for the last quarter are 0.50 USD per share, whereas the estimation was −0.35 USD resulting in a 243.68% surprise. The estimated earnings for the next quarter are −0.37 USD per share. See more details about Abeona Therapeutics Inc. earnings.
Abeona Therapeutics Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 100.00 K USD. In the next quarter, revenue is expected to reach 0.00 USD.
ABEO net income for the last quarter is −9.29 M USD, while the quarter before that showed −30.27 M USD of net income which accounts for 69.30% change. Track more Abeona Therapeutics Inc. financial stats to get the full picture.
No, ABEO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 19, 2025, the company has 136 employees. See our rating of the largest employees — is Abeona Therapeutics Inc. on this list?
Like other stocks, ABEO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Abeona Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Abeona Therapeutics Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Abeona Therapeutics Inc. stock shows the sell signal. See more of Abeona Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.